[1]李 尧,白 鹏,向守卫,等.颈动脉肌纤维发育不良研究进展[J].介入放射学杂志,2020,29(12):1271-1275.
 LI Yao,BAI Peng,XIANG Shouwei,et al.Research progress in fibromuscular dysplasia of the carotid artery[J].journal interventional radiology,2020,29(12):1271-1275.
点击复制

颈动脉肌纤维发育不良研究进展()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年12
页码:
1271-1275
栏目:
综述
出版日期:
2020-12-25

文章信息/Info

Title:
Research progress in fibromuscular dysplasia of the carotid artery
作者:
李 尧 白 鹏 向守卫 邹杨鸿 余化霖
Author(s):
LI Yao BAI Peng XIANG Shouwei ZOU Yanghong YU Hualin.
Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province 650032, China
关键词:
【关键词】 颈动脉 肌纤维发育不良 颅内动脉瘤 动脉夹层
文献标志码:
A
摘要:
【摘要】 肌纤维发育不良(FMD)是一种发生于动脉壁肌组织的特发性、节段性、非动脉粥样硬化性疾病,可导致中小动脉狭窄。FMD主要发生于中青年女性,也见于男性和儿童。该病最常侵犯颈动脉(颈内动脉颅外段)和肾动脉,肠系膜动脉、主动脉、上肢动脉、下肢动脉、冠状动脉等也可受累。颈动脉FMD在临床上不常见,容易漏诊和误诊,其常表现为颈动脉狭窄,且可伴头颈部血管疾病,如动脉瘤、动脉夹层和动静脉瘘。颈动脉FMD诊断主要通过影像学检查,治疗方法包括药物保守治疗、血管内介入治疗和手术治疗。现就目前国际上对颈动脉FMD的最新认识及相关争议,作一综述。

参考文献/References:

[1] Leadbetter WF, Burkland CE. Hypertension in unilateral renal disease[J]. J Urol, 1938, 39: 611- 626.
[2] Olin JW, Froehlich J, Gu X, et al. The United States registry for fibro muscular dysplasia: results in the first 447 patients[J]. Circulation, 2012, 125: 3182-3190.
[3] Gornik HL, Persu A, Adlam D, et al. First international consensus on the diagnosis and management of fibromuscular dysplasia[J]. Vasc Med, 2019, 24: 164-189.
[4] Olin JW, Sealove BA. Diagnosis, management, and future deve-lopments of fibromuscular dysplasia[J]. J Vasc Surg, 2011, 53: 826-836.
[5] Schievink WI, Bjornsson J. Fibromuscular dysplasia of the internal caroti d artery:a clinicopathological study[J]. Clin Neuropathol, 1996, 15: 2- 6.
[6] Shivapour DM, Erwin P, Kim E. Epidemiology of fibromuscular dyspl Asia: a review of the literature[J]. Vasc Med, 2016, 21: 376-381.
[7] Touze E, Oppenheim C, Trystram D, et al. Fibromuscular dysplasia of cer vical and intracranial arteries[J]. Int J Stroke, 2010, 5: 296-305.
[8] Bender MT, Hurtado C, Jiang B, et al. Safety assessment of endovascular treatment of cerebral aneurysms in patients with fibromuscular dysplas ia[J]. Interv Neurol, 2018, 7: 110-117.
[9] Plouin PF, Perdu J, La Batide-Alanore A, et al. Fibromuscular dysplasia[J]. Orphanet J Rare Dis, 2007, 2: 28.
[10] Khoury MH, Gornik HL. Fibromuscular dysplasia(FMD)[J]. Vasc Med, 2017,22: 248-252.
[11] Bujenovic LS. Renovascular hypertension: a noninvasive screening approach using captopril renography[J]. J Am Board Fam Pract, 1995, 8: 295-299.
[12] Ram CV, Clagett GP, Radford LR. Renovascular hypertension[J]. Semin Nephrol, 1995, 15: 152-174.
[13] Green R, Gu X, Kline-Rogers E, et al. Differences between the pediatric and adult presentation of fibromuscular dysplasia: results from the US registry[J]. Pediatr Nephrol, 2016, 31: 641- 650.
[14] Brinza EK, Gornik HL. Fibromuscular dysplasia: advances in understanding and management[J]. Cleve Clin J Med, 2016, 83: 45-51.
[15] Narula N, Kadian- Dodov D, Olin JW. Fibromuscular dysplasia: contempor ary concepts and future directions[J]. Prog Cardiovasc Dis, 2018, 60: 580-585.
[16] Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association[J]. Circulation, 2014, 129: 1048-1078.
[17] Plouin PF, Baguet JP, Thony F, et al. High prevalence of multiple arterial bed lesions in patients with fibromuscular dysplasia: the ARCADIA registry(assessment of renal and cervical artery dysplasia)[J]. Hypertension, 2017, 70: 652- 658.
[18] Kiando SR, Tucker NR, Castro-Vega LJ, et al. PHACTR1 is a genetic susceptibility locus for fibromuscular dysplasia supporting its complex genetic pattern of inheritance[J]. PLoS Genet, 2016, 12: e1006367.
[19] Ganesh SK, Morissette R, Xu Z, et al. Clinical and biochemical profiles suggest fibromuscular dysplasia is a systemic disease with altered TGF- β expression and connective tissue features[J]. FASEB J, 2014, 28: 3313-3324.
[20] O’connor S, Gornik HL, Froehlich JB, et al. Smoking and adverse outcomes in fibromuscular dysplasia: U.S. registry report[J]. J Am Coll Cardiol, 2016, 67: 1750-1751.
[21] Savard S, Azarine A, Jeunemaitre X, et al. Association of smoking with phenotype at diagnosis and vascular interventions in patients with renal artery fibromuscular dysplasia[J]. Hypertension, 2013, 61: 1227-1232.
[22] Kincaid OW, Davis GD, Hallermann FJ, et al. Fibromuscular dysplasia of the renal arteries. Arteriographic features,classifi-cation,and observations on natural history of the disease[J]. Am J Roentgenol Radium Ther Nucl Med, 1968, 104: 271-282.
[23] Persu A, Touze E, Mousseaux E, et al. Diagnosis and management of fibromuscular dysplasia: an expert consensus[J]. Eur J Clin Invest, 2012, 42: 338-347.
[24] Harrison EJ, McCormack LJ. Pathologic classification of renal arterial disease in renovascular hypertension[J]. Mayo Clin Proc, 1971, 46: 161- 167.
[25] De Groote M, Van der Niepen P, Hemelsoet D, et al. Fibromu-scular dysplasia:results of a multicentre study in Flanders[J]. Vasa, 2017, 46: 211-218.
[26] O’connor SC. Poria N,Gornik HL. Fibromuscular dysplasia:an update for the headache clinician[J]. Headache, 2015, 55: 748-755.
[27] Persu A, Giavarini A, Touze E, et al. European consensus on the diagnosis and management of fibromuscular dysplasia[J]. J Hyper-tens, 2014, 32: 1367-1378.
[28] Kadian- Dodov D, Gornik HL, Gu X, et al. Dissection and aneurysm in patients with fibromuscular dysplasia: findings from the U.S.registry for FMD[J]. J Am Coll Cardiol, 2016, 68: 176-185.
[29] Sharma AM, Kline B. The United States registry for fibromuscular dysplasia: new findings and breaking myths[J]. Tech Vasc Interv Radiol, 2014, 17: 258-263.
[30] Olin JW, Kadian- Dodov D. Fibromuscular dysplasia:looking beyond the“string of beads”[J]. JACC Cardiovasc Imaging, 2017, 10: 562-564.
[31] 刘志红,孙友霞,张鸿祺. 颈内动脉肌纤维发育不良的诊断及个体化治疗[J]. 介入放射学杂志, 2013, 22:887-890.
[32] Ho AL, Lin N, Frerichs K, et al. Smoking and intracranial aneurysm morphology[J]. Neurosurgery, 2015, 77: 59- 66.
[33] Nakamura Y, Yamaguchi Y, Makita N, et al. Clinical and radiological characteristics of intracranial artery dissection using recently proposed diagnostic criteria[J]. J Stroke Cerebrovasc Dis, 2019, 28: 1691-1702.
[34] Sethi SS, Lau JF, Godbold J, et al. The Scurve:a novel morpho-logical finding in the internal carotid artery in patients with fibromuscular dysplasia[J]. Vasc Med, 2014, 19: 356-362.
[35] CiuricaS, Lopez- Sublet M, Loeys BL, et al. Arterial tortuosity[J]. Hypertension, 2019, 73: 951- 960.
[36] Alhalabi K, Menias C, Hines R, et al. Imaging and clinical findings in segmental arterial mediolysis(SAM)[J]. Abdom Radiol, 2017, 42: 602- 611.
[37] Hall ET, Gibson BA, Hennemeyer CT,et al. Segmental arterial mediolysis and fibromuscular dysplasia: what comes first,the chicken or the egg?[J]. Cardiovasc Pathol, 2016, 25: 113-115.
[38] Morita T, Maki Y, Notohara K, et al. Subarachnoid hemorrhage from a distal middle cerebral artery aneurysm possibly related to segmental a rterial mediolysis[J]. World Neurosurg, 2019, 122: 429-432.
[39] Shinoda N, Hirai O, Mikami K, et al. Segmental arterial mediolysis involving both vertebral and middle colic arteries leading to subarachnoid and intraperitoneal hemorrhage[J]. World Neuro-surg, 2016, 88: 694.e5-694.e10.
[40] Van der Niepen P, van Tussenbroek F, Devos H, et al. Visceral fibromuscular dysplasia:from asymptomatic disorder to emergency[J]. Eur J Clin Invest, 2018, 48: e13023.
[41] O’connor SC. Gornik HL. Recent developments in the unders-tanding and management of fibromuscular dysplasia[J]. J Am Heart Assoc, 2014, 3: e001259.
[42] Weinberg I, Gu XK, Giri J, et al. Anti- platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: results from the United States registry for fibromus-cular dysplasia[J]. Vasc Med, 2015, 20: 447-453.
[43] Pasquini M, Trystram D, Nokam G, et al. Fibromuscular dysplasia of cervicocephalic arteries: prevalence of multisite involvement and prognosis[J]. Rev Neurol(Paris), 2015, 171: 616-623.
[44] de Bray JM, Marc G, Pautot V, et al. Fibromuscular dysplasia may herald symptomatic recurrence of cervical artery dissection[J]. Cerebrovas Dis, 2007, 23: 448-452.

相似文献/References:

[1]李应龙,庞尊中,何 强,等.经颈动脉腔内治疗腹主动脉瘤腔内隔绝术后内漏一例[J].介入放射学杂志,2014,(08):743.
 LI Ying long,PANG Zun zhong,HE Qiang,et al.Successful endovascular treatment via carotid for endoleak due to endovascular graft exclusion of abdominal aortic aneurysm: report of one case[J].journal interventional radiology,2014,(12):743.
[2]郭建明,李俊峰,谷涌泉,等.内膜剥脱联合支架成形治疗颈动脉串联病变 [J].介入放射学杂志,2015,(10):910.
 GUO Jian- ming,LI Jun- feng,GU Yong- quan,et al.Carotid endarterectomy combined with stent angioplasty for the treatment of tandem stenosis of carotid artery[J].journal interventional radiology,2015,(12):910.

备注/Memo

备注/Memo:
(收稿日期:2019-11-26)
(本文编辑:边 佶)
更新日期/Last Update: 2020-12-16